Facio strengthens its Board
Facio Therapies announces that Otto Postma has been appointed to the Board of FSHD Unlimited as per February 11, 2016.
FSHD Unlimited is the parent company of both Facio Therapies and Facio Intellectual Property. Its shareholders have unanimously approved the nomination of Otto Postma for membership of the Board. With his appointment, the Board now consists of Kees van der Graaf, Bill Moss AO, Neil Camarta and Otto Postma.
“We are very pleased that Otto joins the Board”, said Kees van der Graaf, Chairman of the Board. “As a strategic advisor, Otto has been instrumental in the establishment of the Facio group. His long-lasting business and corporate finance expertise in the medical life science sector brings important value to the Board and will definitely help to drive the Facio group to fulfilling its ambition: the development of an affordable causal therapy for as many people with FSHD as possible.”
Otto Postma is a Managing Director of MedSciences Capital, an investment fund of the Amsterdam-based merchant bank Kempen & Co, providing equity funding to emerging life science companies. Prior, Otto co-founded (the predecessor of) Pharming Group NV, where he held various management positions in the fields of business and corporate development.